OsteoAMP is an allograft-derived growth factor that can be used as an alternative to recombinant growth factors, such as rhBMP-2 and allograft-derived stem cells, such as Osteocel Plus.
A retrospective analysis was conducted of 140 consecutive patients that had undergone cervical spine fusions using OsteoAMP. In dependent radiologists assessed fusion at 3 months, 6 months, 12 months and 18 months.
The study showed that 80 percent of patients had evidence of fusions at 6 months, 98 percent of patients had evidence of fusions at 12 months, and 100 percent of patients had evidence of fusions at 18 months.
More Articles on Devices:
Mazor Robotics 2013 Net Loss Shoots to $20M
Advancement in Lateral Spine Technology: Q&A with Vertebral Technologies, Inc. CEO Dr. Jeffrey Felt
EDGE Orthopaedics Receives FDA 510(k) Clearance for BITE Compression Screws
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
